4 Healthcare Stock Stories Prescribed To Savvy Investors

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Gilead Sciences (NASDAQ:GILD): Closing price $56.18

On Tuesday, Gilead announced that the European Commission has awarded marketing authorization for Stribild (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir disoproxil (as fumarate) 245 mg), which is a single tablet regimen for the treatment of HIV-1 infection in adults who are antiretroviral treatment-naïve or are infected with HIV-1 without known mutations associated with resistance to any of the three antiretroviral agents in Stribild. This authorization permits the marketing of Stribild in all 27 countries of the European Union.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

GILD

Neuralstem (AMEX:CUR): Closing price $1.40

Neuralstem said that a paper published Tuesday in the journal, Stem Cell Research and Therapy, demonstrated that rats transplanted with its spinal cord-derived human neural stem cells, NSI-566, three days after a spinal cord injury at L3 (lumbar 3), indicated improvement along a number of measures of motor function and a reduction of spasticity. The study, Amelioration of Motor/Sensory Dysfunction and Spasticity in a Rat Model of Acute Lumbar Spinal Cord Injury by Human Neural Stem Cell Transplantation, was conducted by principal investigator, Martin Marsala, M.D., of the University of California, San Diego School of Medicine.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

CUR

BG Medicine (NASDAQ:BGMD): Closing price $1.95

BG Medicine has announced the presentation of new clinical research data on the BGM Galectin-3 test in heart disease at the 2013 European Society of Cardiology Heart Failure Congress (ESC-HF) in Lisbon. Included in the highlights was a late-breaking oral presentation of results from the Aldo-DHF Biomarker Substudy, which showed the usefulness of galectin-3 testing for assessing functional capacity and clinical prognosis in patients identified with a form of heart failure known as Heart Failure with Preserved Ejection Fraction. Heart Failure with Preserved Ejection Fraction is the most rapidly-growing type of clinical heart failure in the United States and Europe, disproportionately impacting women and comprising one-third to one-half of all hospital admissions for heart failure.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

BGMD

Alexion Pharmaceuticals (NASDAQ:ALXN): Closing price $101.19

Alexion’s subsidiary Alexion Pharma International Sàrl, on Tuesday announced that the FDA has awarded Breakthrough Therapy designation to asfotase alfa for the treatment of patients suffering from hypophosphatasia whose first signs or symptoms occurred before 18 years of age, including perinatal-, infantile-, and juvenile-onset forms of the disease. HPP is an inherited, life-threatening,  extremely rare metabolic disorder that leads to progressive damage to multiple vital organs, among which include destruction and deformity of bones.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

ALXN

Don’t Miss: Will Obamacare’s Insurance Exchanges Be a Bust?

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business